US revenue for the fourth quarter stood at $70 million, flat sequentially and lower than the $77 million reported in the year-ago quarter. For the full year, US revenue came in at $284 million compared to $291 million in FY25.
The company, however, reiterated its long-term North America revenue target of $375–400 million by FY28 and said growth is expected to recover from H2FY27 onwards.In contrast, the Ex-US business continued to emerge as the key growth driver for the company.
Ex-US revenue rose to $70 million in the fourth quarter from $64 million in the previous quarter and $57 million a year ago. The contribution of Ex-US markets to overall sales increased to 46% in FY26 from 41% in FY24.
The management said Ex-US markets are expected to grow faster than the US business going ahead, supported by strong momentum across key geographies.The company also said EBITDA margins improved to around 19% during FY26 and reiterated its guidance of achieving 20%-plus margins ahead.
The commentary comes after Strides Pharma reported a consolidated net profit of ₹129.2 crore for the fourth quarter, up 51% year-on-year from ₹86 crore in the corresponding quarter last year.
Revenue for the quarter rose 11.2% to ₹1,323.4 crore from ₹1,190.3 crore a year ago, while EBITDA increased 10% to ₹239.6 crore from ₹218 crore.
For FY26, Ex-US market revenue rose 21% year-on-year to ₹2,240.4 crore, while US market revenue grew 2% to ₹2,489.7 crore.
Managing Director and Group CEO Badree Komandur said the company delivered strong profitability and efficiency metrics during FY26, driven by robust momentum in Ex-US markets.
The board has recommended a final dividend of ₹5 per equity share for FY26.
Shares of Strides Pharma reacted to the results announced after market hours on Monday, falling sharply to hit an intraday low of ₹1,035 on Tuesday morning. The stock is now off the day’s lows and was trading at ₹1,117, still about 3% lower. It has, however, gained 12% over the past month and 63% in the last year.
